格隆汇1月30日丨恒瑞医药(01276.HK)发布公告，2026年1月30日耗资人民币1996万元回购34.31万股A 股，回购价格每股58.12-58.21元。 ...

Market Performance - The Hong Kong stock index opened lower and continued to decline, closing down 2.08% at 27,387.11 points, while the Hang Seng Tech Index fell 2.1% to 5,718.18 points [1] - Major technology stocks experienced declines, with Alibaba down 2.37%, Tencent down 2.57%, and JD Group down 1.92% [1] - Gold stocks plummeted, with Chifeng Jilong Gold Mining down over 14% and Shandong Gold Mining down over 14% [1] - Lithium mining stocks also fell, with Ganfeng Lithium down nearly 11% and Tianqi Lithium down over 10% [1] - Education and storage chip concepts rose, with New Oriental up 5.52% and China Spring up 22.76% [1] Company Insights - Guoquan (02517.HK) expects revenue of approximately 7.75 billion to 7.85 billion yuan in 2025, a year-on-year increase of about 19.8% to 21.3%, with net profit projected at 443 million to 463 million yuan, up 83.7% to 92.0% [2] - Hengrui Medicine (01276.HK) has received acceptance for a new indication application for its innovative drug, which may provide a new treatment option for patients with unresectable liver cancer [2] - Gilead Sciences-B (01672.HK) reported positive top-line results for its oral FASN inhibitor in treating acne [2] - Baiaosaitu-B (02315.HK) anticipates revenue of 1.369 billion to 1.389 billion yuan in 2025, a year-on-year increase of 39.61% to 41.65%, with net profit expected to rise by 384.26% to 443.88% [2] - Nocera (09969.HK) expects total revenue of approximately 2.365 billion yuan in 2025, a year-on-year growth of about 134%, and aims to achieve profitability with a net profit of around 633 million yuan [2] Financial Projections - Dazhong Public Utilities (01635.HK) projects net profit between 350 million to 500 million yuan in 2025, an increase of 50.12% to 114.46% [3] - Chunli Medical (01858.HK) expects net profit of 245 million to 288 million yuan in 2025, a rise of 96.01% to 130.41% [3] - Yujian Xiaomian (02408.HK) anticipates net profit between 100 million to 115 million yuan in 2025, an increase of approximately 64.7% to 89.5% [4] - China Railway (00390.HK) has recently won several major projects with a total bid amount of approximately 43.292 billion yuan [5] - Sunny Optical Technology (02382.HK) expects net profit between 4.5886 billion to 4.7235 billion yuan in 2025, a year-on-year increase of about 70.0% to 75.0% [6] - New天绿色能源 (00956.HK) expects to complete a cumulative power generation of 15.2104 million MWh in 2025, a year-on-year increase of 7.71% [7] Institutional Views - Guoyuan International suggests that Hong Kong stocks may continue to outperform U.S. stocks due to fiscal cliff and geopolitical factors, benefiting from a trend of diminishing dollar credit [8] - Huatai Securities believes that technology and cyclical "consumables" are likely to lead the rebound in Hong Kong stocks, supported by improved macro data and stable funding conditions [9] - CITIC Securities anticipates that the spring market for Hong Kong stocks will continue, with large-cap stocks showing relative gains and growth sectors supported by policy performing better [9]

恒瑞医药（600276）(01276)发布公告，于2026年1月30日，该公司斥资人民币1995.99万元回购34.31万 股A股股份，每股回购价人民币58.12-58.21元。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，于2026年1月30日，该公司斥资人民币1995.99万元回购 34.31万股A股股份，每股回购价人民币58.12-58.21元。 ...

Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 831.03%, Zhejiang Shibao (01057) at 339.32%, and Sinopec Oilfield Service (01033) at 323.71% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -14.62%, China Merchants Bank (03968) at -3.22%, and Hengrui Medicine (01276) at 1.77% [1][2] - Sinopec Oilfield Service (01033), Andeli Juice (02218), and Shandong Molong (00568) have the highest deviation values at 53.41%, 21.68%, and 19.01% respectively [1][2] Group 2 - The companies with the lowest deviation values include Zhejiang Shibao (01057) at -58.91%, Yangtze Optical Fibre and Cable (06869) at -49.00%, and Fudan Zhangjiang (01349) at -24.81% [1][2][4] - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) and Beijing Electromechanical (00187) with premium rates of 258.91% and 257.99% respectively [2] - The bottom ten AH stocks by premium rate include Weichai Power (02338) and Midea Group (00300) with premium rates of 6.84% and 8.51% respectively [2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2026年1月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Group 1 - The pharmaceutical sector experienced a pullback, with the pharmaceutical ETF (159929) declining by 1.53% and a trading volume exceeding 1.3 billion yuan, indicating a net inflow of over 45 million yuan during the day, marking 11 consecutive days of capital inflow totaling over 360 million yuan [1][3] - Major stocks within the pharmaceutical ETF saw most decline, including Meien Health and Pianzaihuang dropping over 3%, WuXi AppTec and Aier Eye Hospital falling over 2%, while Tigermed rose over 7% [3][4] - Tigermed is projected to see a net profit growth of 105% to 204% by 2025, indicating strong future performance [3] Group 2 - The JPM 2026 conference highlighted a shift in the global pharmaceutical industry's focus towards the effective allocation and long-term value realization of innovations amidst rising uncertainties [5] - Chinese innovation is gaining global recognition, with increased participation from Chinese companies at the JPM 2026, reflecting a growing acknowledgment from international capital and multinational pharmaceutical companies [5][6] - The evaluation logic of multinational pharmaceutical companies regarding Chinese innovative assets is evolving, focusing on their efficacy, differentiation, and competitive positioning for inclusion in global product portfolios [6][10] Group 3 - Multinational pharmaceutical companies are entering a critical patent cliff period, necessitating diversification in their pipelines to mitigate risks associated with single products and treatment areas [10][12] - The integration of AI into core strategies is becoming mainstream, with AI being utilized to enhance R&D efficiency and optimize operational systems, thus addressing challenges posed by the patent cliff [12][13] - The oncology sector remains a core area for pharmaceutical innovation, with a focus on antibody-drug conjugates (ADCs) and cell therapies, indicating a robust pipeline and commercial potential [13][15]

Market Performance - The Hong Kong stock market opened lower on January 30, with the Hang Seng Index dropping by 496.82 points, a decline of 1.78%, closing at 27,471.27 points [1] - The Hang Seng Tech Index fell by 104.83 points, down 1.79%, to 5,736.27 points, while the National Enterprises Index decreased by 2.08% to 9,354.3 points [1] - Major tech stocks experienced declines, with Alibaba down 2.71%, Tencent down 1.53%, and JD Group down 1.4% [1] Company Earnings Forecasts - Guoquan (02517.HK) expects revenue for 2025 to be approximately 7.75 billion to 7.85 billion yuan, a year-on-year increase of about 19.8% to 21.3%, with net profit projected at 443 million to 463 million yuan, up 83.7% to 92.0% [2] - Sunny Optical Technology (02382.HK) anticipates a net profit of 4.5886 billion to 4.7235 billion yuan for 2025, representing a year-on-year increase of approximately 70.0% to 75.0% [3] - Baidu (02315.HK) forecasts revenue of 1.369 billion to 1.389 billion yuan for 2025, with a net profit of 162 million to 182 million yuan, reflecting a significant increase of 384.26% to 443.88% [3] - Spring Medical (01858.HK) expects a net profit of 245 million to 288 million yuan for 2025, an increase of 96.01% to 130.41% [4] - Encounter Small Noodles (02408.HK) projects a net profit between 100 million to 115 million yuan for 2025, an increase of approximately 64.7% to 89.5% [5] - Macro Credit Development (09930.HK) issued a profit warning, expecting a decline in shareholder profit by 70% to 90% for 2025 [6] - Financial Street Securities (01476.HK) issued a profit alert, expecting a shareholder profit increase to approximately 327 million yuan for 2025 [7] Industry Insights - China Railway (00390.HK) recently won several major engineering contracts with a total bid amount of approximately 43.292 billion yuan [8] - New天绿色能源 (00956.HK) reported a cumulative power generation of 15.2104 million MWh for 2025, a year-on-year increase of 7.71% [9] - Huayi Pharmaceutical (01276.HK) received acceptance for a new indication application for its innovative drug, which may become a new treatment option for patients with unresectable liver cancer [9] - Citic Securities suggests focusing on three main lines in the short term: biomanufacturing, embodied intelligence, and 6G technology [11] - Guoyuan International believes that the Hong Kong stock market may continue to outperform the US market due to factors such as fiscal cliffs and geopolitical issues, benefiting from the low long-term valuation levels [12]

Summary of Key Points from the Conference Call Industry Overview - The overall positioning of the pharmaceutical industry in 2026 is "innovation first, with drugs and devices flying together," indicating a more diversified market compared to 2025 [2] - The investment in innovative drugs requires careful selection, with the current market conditions presenting a good opportunity for entry after adjustments at the beginning of the year [3] Company Insights - Biofarma companies are highlighted as better investment choices due to their combination of R&D innovation, certainty, and long-term growth potential. The record-breaking BD amount in 2025 indicates a positive cycle of capital inflow into R&D [6] - Companies like 康方 (Kangfang), 百济神州 (BeiGene), and 英恩生物 (InnoCare) are expected to achieve commercial breakthroughs or expand internationally in the coming years [20] Market Trends - The global innovative drug development cycle is just beginning, with Chinese companies expected to account for 40% of transaction amounts by 2025, indicating a strong role in the global market [5] - The second-generation immune checkpoint inhibitors (IO) market is projected to reach $120 billion within the next decade, with significant participation from Chinese innovative drugs [12] Technological Advancements - Emerging technologies such as small nucleic acid therapies, molecular glue, gene editing, and long-acting drugs are expected to see significant development in 2026 [11][18] - Dual-specific antibodies and antibody-drug conjugates (ADC) are highlighted as promising treatment options for various cancers, including triple-negative breast cancer and small cell lung cancer [16][14] Policy and Regulatory Environment - The Chinese healthcare negotiation supports emerging therapies, including ADCs and siRNA, which are included in the healthcare directory, promoting self-sustaining funding and attracting more investors [7] Investment Opportunities - The report emphasizes the importance of focusing on companies with clear growth potential and stable revenue expectations, particularly those with significant upcoming data releases [26] - Notable companies to watch include 康诺亚 (Conway), 康弘 (Kanghong), and 毕比特 (BIBIT), which are considered to have strong upside potential [24] Conclusion - The future growth of companies in the pharmaceutical sector will rely on their global ecosystem platforms and the continuous iteration of their pipeline priorities, with a focus on high-potential projects [22]

消息面上，民政部印发《关于进一步推进民政科技创新的指导意见》，其中提到，广泛应用人形机器 人、脑机接口、人工智能等前沿技术，开展失能失智预防和抗衰老、生活照料和康复护理、精神慰藉和 社会参与促进、安全风险监测和紧急救援、老年宜居环境建设和适老化改造等方面关键技术装备研发。 截至2026年1月30日 10:05，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，海思科领涨 2.62%，新产业上涨1.67%，华润三九上涨0.96%；片仔癀领跌。医疗创新ETF(516820)最新报价0.36元。 规模方面，医疗创新ETF最新规模达18.67亿元，创近1年新高。从资金净流入方面来看，医疗创新ETF 近10天获得连续资金净流入，最高单日获得4182.65万元净流入，合计"吸金"1.86亿元，日均净流入达 1857.56万元。（数据来源：Wind） 招商证券指出，脑机接口技术已从长期学术探索阶段进入产业拐点，在政策与需求双重驱动下，医疗成 为其核心主战场，占全球应用场景的56%；中国脑机接口产业在系统集成与应用落地方面进展显著， 2025年被正式纳入"十五五"规划中的"六大未来产业"，顶层设计与地方支持同步加 ...